Keyword: Deerfield Management
Deerfield is set to take control of Melinta as payment for the $140 million loan it extended to the antibiotics business.
Civetta Therapeutics is launching with $53 million from Deerfield to develop drugs targeting beta-propeller proteins with a first focus in cancer.
Deerfield plans to create 300,000 square-feet of life sciences space at the 12-story building.
Nkarta now has the runway to start clinical trials for its natural killer cell therapy, build a manufacturing site and advance its early-stage pipeline.
The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.
Frontier Medicines launched with $67 million and a mission to find drug-binding pockets on previously undruggable proteins.
Acutus secured $170 million after acquiring a catheter developer and announcing a slew of new partnerships in arrhythmia treatment and monitoring.
The $130 million is to be funneled over a 10-year period through a new company borne of the alliance known as Hudson Heights Innovations.
Deerfield is contributing up to $65 million to create a company to speed the route to market for drugs discovered at the University of Illinois at Chicago.
Deerfield Management and Harvard University are setting up a new company dubbed Lab1636, with $100 million in backing from Deerfield.